Please visit the vantage homehalaman for our latest articltape or mencari our articltape via the buttomenjadi below.

Vantage homehalaman mencari articles




Anda sedang menonton: Pt. pratapa nirmala fahrenheit

*


Krystal shinpita in epidermolysis bullosa

Look out Amryt: Krystal’s topical gen therapy is gaining ground.


*


Biggest unpartnered assets: Argenx nears crunch time

Amid cautionary talpita of other highly valued unpartnered assets, efgartigimod approachpita pengukur its US date with destiny.


*

Merck boosts Pfizer’s Covid antiviral advantage

Efficacy of Merck/Ridgeback’s molnupiravir shows an alarming fall-off, just as a US regulatory panel tinjauannya beckons.


Covid-19 scramblpita big medtech’s spendingi

Roche, its coffers sepenuhnya from coronavirus test sales, ups its remencari spendingi – but Baxter cuts back.


Gilead pause adds to Merck’s HIV doubts

could Gilead soon be looraja for a new partner for its long-actingai project lenacapavir?


A radical strategy for Medtronic

The sellside expects the world’s leading medtech to be outpaced by its rivals. Divestments might allow the group to defy this destiny.


Neurocrine gets selective in schizophrenia

The group’s deal with Sosei will see it compete with Karuna and Cerevel.


Healthineers scorpita big in the third quarter

Diagnostics companipita pengukur enjoy notable uplift in sales; elsewhere, spinouts bisa shape the future.


The bubble bursts for biotech stocks

After a frothy couple of years, biotechs are no longer seeinew york big boosts from clinical data.


Daiichi bisa be rewarded for persistingai with Vanflyta

A front-line trial yields a positive result two years after the drug got a US complete response letter.




Lihat lainnya: Perut Sakit Jika Ditekan Di Bawah Pusar, Perut Bagian Bawah Pusar Sakit

We use cookitape on this website. By usingi this site, you agree that we may store and access cookies on your device. Find out more.